Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine.
Studies were undertaken to determine the therapeutic effects of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine (lip-ara-C) against intracranial L1210 leukemia. The effects of administration route, drug dosage, liposome type, and tumor load on therapeutic efficacy were also studied. One hundred % mice were cured after a single intracranial 40 mg/kg dose of lip-ara-C, dependent on tumor load. Intracranial lip-ara-C was more effective than i.v. lip-ara-C. A single i.v. dose of lip-ara-C was therapeutically superior to 5-day i.v. infusion of the free drug. Intracranial or i.v. lip-ara-C at therapeutic doses resulted in less systemic toxicity than i.v. infusion of free ara-C, suggesting possible use of lip-ara-C as an adjunct to treatment of central nervous system leukemia.
Department of Experimental Pathology, Roswell Park Memorial Institute, Buffalo, New York 14263.
F
F
Hong
E
E
Mayhew
D000818:Animals; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D001932:Brain Neoplasms / Q000188:drug therapy / Q000556:secondary*; D003561:Cytarabine / Q000008:administration & dosage* / Q000627:therapeutic use / Q000633:toxicity; D004337:Drug Carriers; D007421:Intestine, Small / Q000187:drug effects / Q000473:pathology; D007939:Leukemia L1210 / Q000188:drug therapy*; D008081:Liposomes; D051379:Mice
D004337:Drug Carriers; D008081:Liposomes; D003561:Cytarabine